argenx SE ARGX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:43 PM EDT
375.14quote price arrow up+19.13 (+5.37%)
Volume
291,944
52 week range
327.73 - 550.76
Loading...
  • Open359.41
  • Day High380.75
  • Day Low359.41
  • Prev Close356.01
  • 52 Week High550.76
  • 52 Week High Date07/21/23
  • 52 Week Low327.73
  • 52 Week Low Date12/21/23

Key Stats

  • Market Cap22.295B
  • Shares Out59.43M
  • 10 Day Average Volume0.30M
  • Dividend-
  • Dividend Yield-
  • Beta0.64
  • YTD % Change-1.67

KEY STATS

  • Open359.41
  • Day High380.75
  • Day Low359.41
  • Prev Close356.01
  • 52 Week High550.76
  • 52 Week High Date07/21/23
  • 52 Week Low327.73
  • 52 Week Low Date12/21/23
  • Market Cap22.295B
  • Shares Out59.43M
  • 10 Day Average Volume0.30M
  • Dividend-
  • Dividend Yield-
  • Beta0.64
  • YTD % Change-1.67

RATIOS/PROFITABILITY

  • EPS (TTM)-5.68
  • P/E (TTM)-66.05
  • Fwd P/E (NTM)-122.28
  • EBITDA (TTM)-408.785M
  • ROE (TTM)-8.54%
  • Revenue (TTM)1.408B
  • Gross Margin (TTM)89.87%
  • Net Margin (TTM)-23.28%
  • Debt To Equity (MRQ)0.49%

EVENTS

  • Earnings Date07/25/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On argenx SE

 

Profile

MORE
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor...
Peter Verhaeghe
Non-Executive Independent Chairman of the Board
Tim Van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Karen Massey
Chief Operating Officer
Karl Gubitz
Chief Financial Officer
Malini Moorthy
General Counsel
Address
Laarderhoogtweg 25
Amsterdam
1101 EB
Netherlands